Lurbinectedin is a chemotherapy drug that is used to treat patients with certain types of cancer, including small cell lung cancer and ovarian cancer. According to Drug Patent Watch [1], lurbinectedin is currently being studied in combination with other chemotherapy drugs, including doxorubicin and paclitaxel, to determine if these combinations can improve treatment outcomes for patients.

Clinical trials [2] have shown that lurbinectedin in combination with doxorubicin has been effective in treating patients with relapsed small cell lung cancer. In a phase II trial, the combination of lurbinectedin and doxorubicin resulted in an overall response rate of 64%, with a median progression-free survival of 5.3 months.

Another study [3] has suggested that lurbinectedin in combination with paclitaxel may also be effective in treating patients with ovarian cancer. In a phase II trial, the combination of lurbinectedin and paclitaxel resulted in an overall response rate of 46%, with a median progression-free survival of 5.3 months.

It is important to note that while these studies have shown promising results, further research is needed to determine the optimal treatment regimens for lurbinectedin. Additionally, it is important to discuss all treatment options with a healthcare provider to determine the best course of action for each individual patient.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c82382
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346176/